Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1974
Title: Role of renin–angiotensin system antagonists on long-term mortality post-percutaneous coronary intervention in reduced and preserved ejection fraction.
Author: Prosser, H.
Peck, K.
Dinh, D.
Roberts, L.
Chandrasekhar, J.
Brennan, A.
Duffy, S.
Clark, D.
Ajani, A.
Oqueli, Ernesto
Sebastian, M.
Reid, C.
Freeman, M.
Sajeev, J.
Teh, A.
Issue Date: 2022
Publication Title: Clinical Research in Cardiology
Volume: 111
Issue: 7
Start Page: 776
End Page: 786
Abstract: Aims The use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II-receptor blockers (ARBs) post-myocardial infarction (MI) is supported by evidence based on trials performed in the thrombolysis era. This was prior to primary percutaneous coronary intervention (PCI) being routine practice, and with little direct evidence for the use of these medications in patients with preserved left ventricular (LV) function. This study sought to determine whether there is an association between ACEi/ARB use after PCI for acute coronary syndrome (ACS) and long-term all-cause mortality, with a particular focus on patients with preserved LV function. Methods This multicentre, observational study evaluated prospectively collected data of 21,388 patients (> 18 years old) that underwent PCI for NSTEMI and STEMI between 2005 and 2018, and were alive at 30 day follow-up. Results In total, 83.8% of patients were using ACEi/ARBs. Kaplan–Meier analysis demonstrated ACEi/ARB use was associated with a significantly lower mortality in the entire cohort (15.0 vs. 22.7%; p < 0.001) with a mean follow-up of 5.58 years; and independently associated with 24% lower mortality by Cox proportional hazards modelling (HR 0.76, CI 0.67–0.85, p < 0.001). ACEi/ARB therapy was also associated with significantly lower mortality in patients with reduced or preserved LV function, with greater survival benefit with worse LV dysfunction. Conclusion ACEi/ARB therapy post-PCI is associated with significantly lower long-term mortality in patients with reduced and preserved LV function. These findings provide contemporary evidence for using these agents in the current era of routine primary PCI, including those with preserved EF.
URI: http://hdl.handle.net/11054/1974
DOI: https://doi.org/10.1007/s00392-021-01985-x
Internal ID Number: 01933
Health Subject: ANGIOTENSIN CONVERTING ENZYME INHIBITORS
ANGIOTENSIN RECEPTOR BLOCKERS
HEART FAILURE
PERCUTANEOUS CORONARY INTERVENTION
STEMI/NSTEMI
Type: Journal Article
Article
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.